Sign in
Taking people in United StatesNo phase

Studies new ways to detect harmful lung bacteria in people with cystic fibrosis

Looks for better ways to find harmful lung bacteria in people with cystic fibrosis.

Key facts

Who runs it
Chris Goss
Where
Columbus, Dallas, La Jolla, Milwaukee, Minneapolis, Omaha, Philadelphia, Pittsburgh, and St Louis, United StatesSee the 9 sites
Trial code
Registry title
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
Status
Recruiting
People taking part
300 people, planned
Started
30 Mar 2026
Expected to end
1 Aug 2027
Type of study
Observational
Record updated
2 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with cystic fibrosis who are 16 or older and can cough up sputum. It tests new ways to find harmful lung bacteria.

Age
16 years or older
Sex
All sexes
Disease stage
Cystic fibrosis with a documented diagnosis. Percent predicted FEV1 must be 30% or higher.

Main reasons for not taking part

  • History of solid organ transplant
  • Active cancer, or cancer treatment, in the 12 months before the study visit
  • Pregnant
  • Cannot cough up sputum

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • ≥ 16 years of age on day of study visit
  • Documentation of CF Diagnosis
  • Able to expectorate sputum
  • Percent predicted FEV1 ≥ 30%

Who cannot take part

  • History of active malignancy (or treatment for malignancy) in 12 months prior to the study visit
  • History of solid organ transplantation
  • Pregnant

Where in United States

  • Nationwide Children's HospitalColumbus, United StatesContact: Diana GilmoreNot yet recruiting
  • University of Texas, SouthwesternDallas, United StatesContact: Ashley KellerTaking people
  • University of California San DiegoLa Jolla, United StatesContact: Jenna MielkeNot yet recruiting
  • Froedtert & Medical College of WisconsinMilwaukee, United StatesContact: Erin HubertzTaking people
  • The Minnesota Cystic Fibrosis CenterMinneapolis, United StatesContact: Nikita MidambaTaking people
  • University of Nebraska Medical CenterOmaha, United StatesContact: Michel VeitNot yet recruiting
  • University of PennsylvaniaPhiladelphia, United StatesContact: Melissa MolterTaking people
  • University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Adrienne DeRiccoTaking people
  • Washington University School of MedicineSt Louis, United StatesContact: Irma BauerTaking people

About the trial

What the trial wants to find out

Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF (SEND-CF)
Plain-language title
Studies new ways to detect harmful lung bacteria in people with cystic fibrosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
2 July 2026